May 31, 2026 – Chicago, Illinois, USA
Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung cancer (NSCLC) treatment programs at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the potential of its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI) DZD6008 and the combination of golidocitinib with an anti-PD-1 antibody. The presentations underscore the company’s commitment to addressing critical unmet needs in lung cancer, particularly among patients who have developed resistance to existing therapies and those with advanced disease requiring more effective treatment options. The latest data demonstrated strong anti-tumor activity, durable clinical responses, and encouraging safety outcomes, positioning both candidates as promising additions to the evolving landscape of precision oncology.
DZD6008 Shows Durable Activity Against EGFR Resistance Mutations
One of the most significant highlights from ASCO 2026 was the oral presentation of DZD6008, an investigational fourth-generation EGFR TKI specifically designed to overcome resistance mechanisms that frequently emerge following treatment with third-generation EGFR inhibitors. Patients with EGFR-mutated NSCLC often develop acquired resistance mutations such as EGFR C797X, which significantly limits the effectiveness of currently available therapies. According to the study findings, 82.1% of patients experienced measurable tumor shrinkage following treatment with DZD6008, demonstrating strong anti-tumor activity in a population with limited therapeutic options.
The clinical data further revealed durable disease control, with six-month progression-free survival rates reaching 70.6% in the 40 mg cohort and 61.8% in the 60 mg cohort. Importantly, the median duration of response had not yet been reached at the time of analysis, indicating the potential for sustained therapeutic benefit. Researchers also reported exceptional blood-brain barrier penetration, a critical factor in NSCLC management given the high prevalence of brain metastases among EGFR-mutated patients. Strong intracranial activity was observed in patients with baseline brain metastases, highlighting DZD6008’s potential to address one of the most challenging aspects of advanced lung cancer treatment. Additionally, the therapy demonstrated a favorable safety profile due to its high selectivity for mutant EGFR while minimizing effects on wild-type EGFR.
Golidocitinib Combination Therapy Enhances Anti-Tumor Response
Advertisement
Dizal also presented encouraging data for golidocitinib, a highly selective JAK1 inhibitor, combined with an anti-PD-1 antibody as a first-line treatment approach for patients with advanced NSCLC lacking actionable driver mutations. Among 47 treatment-naïve patients enrolled in the study, the combination demonstrated durable anti-tumor activity and meaningful clinical benefits, particularly among individuals with high PD-L1 expression. Researchers reported improved treatment responses alongside a notable reduction in immune-related adverse events, an important consideration in immunotherapy-based treatment strategies.
The findings suggest that combining JAK1 inhibition with immune checkpoint blockade may enhance anti-tumor immunity while improving treatment tolerability. This innovative approach could potentially provide a valuable new therapeutic option for patients who do not qualify for targeted therapies based on molecular profiling. The results further strengthen Dizal’s growing oncology pipeline and reinforce the company’s focus on developing differentiated treatment strategies that address complex cancer biology and resistance mechanisms.
Advancing Precision Oncology for Global Lung Cancer Patients
The latest ASCO presentations highlight Dizal’s broader strategy of advancing precision medicine through scientifically differentiated therapies capable of addressing major challenges in lung cancer treatment. With DZD6008 targeting resistance mutations and central nervous system disease, and golidocitinib enhancing immunotherapy outcomes, the company is building a robust portfolio aimed at improving outcomes for patients across multiple stages of NSCLC. As lung cancer remains the leading cause of cancer-related mortality worldwide, innovations that extend disease control, improve survival prospects, and address treatment resistance are increasingly important. The encouraging results presented at ASCO 2026 support continued global clinical development efforts and reinforce the growing role of next-generation targeted therapies and immuno-oncology combinations in transforming cancer care.
Source: Dizal press release
